Akebia Therapeutics, Inc.
AKBA
$1.74
-$0.145-7.71%
| Weiss Ratings | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.40 | |||
| Price History | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -9.64% | |||
| 30-Day Total Return | -3.61% | |||
| 60-Day Total Return | -6.72% | |||
| 90-Day Total Return | -4.67% | |||
| Year to Date Total Return | -8.68% | |||
| 1-Year Total Return | 14.90% | |||
| 2-Year Total Return | 221.89% | |||
| 3-Year Total Return | 163.32% | |||
| 5-Year Total Return | -75.53% | |||
| 52-Week High % Change | -34.95% | |||
| 52-Week Low % Change | 135.00% | |||
| Price | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.89 | |||
| 52-Week Low Price | $0.80 | |||
| 52-Week Low Price (Date) | Jun 26, 2024 | |||
| 52-Week High Price (Date) | Mar 19, 2025 | |||
| Valuation | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 444.11M | |||
| Enterprise Value | 580.97M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.33 | |||
| Earnings Per Share Growth | 17.67% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.57 | |||
| Price/Book (Q) | -8.60 | |||
| Enterprise Value/Revenue (TTM) | 3.63 | |||
| Price | $1.74 | |||
| Enterprise Value/EBITDA (TTM) | -71.61 | |||
| Enterprise Value/EBIT | -12.74 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 218.70M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 871 2098 | |||
| Address | 245 First Street Cambridge, MA 02142 | |||
| Website | www.akebia.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -28.47% | |||
| Profit Margin | -43.33% | |||
| Management Effectiveness | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.33% | |||
| Return on Equity | -- | |||
| Income Statement | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 160.18M | |||
| Total Revenue (TTM) | 160.18M | |||
| Revenue Per Share | $0.73 | |||
| Gross Profit (TTM) | 134.62M | |||
| EBITDA (TTM) | -8.11M | |||
| EBIT (TTM) | -45.62M | |||
| Net Income (TTM) | -69.41M | |||
| Net Income Avl. to Common (TTM) | -69.41M | |||
| Total Revenue Growth (Q YOY) | -17.26% | |||
| Earnings Growth (Q YOY) | -3,814.01% | |||
| EPS Diluted (TTM) | -0.33 | |||
| EPS Diluted Growth (Q YOY) | -3,359.38% | |||
| Balance Sheet | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 51.87M | |||
| Cash Per Share (Q) | $0.24 | |||
| Total Current Assets (Q) | 113.83M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -49.19M | |||
| Current Ratio (Q) | 1.407 | |||
| Book Value Per Share (Q) | -$0.22 | |||
| Total Assets (Q) | 220.67M | |||
| Total Current Liabilities (Q) | 80.91M | |||
| Total Debt (Q) | 188.73M | |||
| Total Liabilities (Q) | 269.86M | |||
| Total Common Equity (Q) | -49.19M | |||
| Cash Flow | AKBA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -33.00K | |||
| Cash from Financing (TTM) | 49.66M | |||
| Net Change in Cash (TTM) | 8.97M | |||
| Levered Free Cash Flow (TTM) | 18.20M | |||
| Cash from Operations (TTM) | -40.66M | |||
